## SNA: Snap-On Incorporated - XLI: Industrials

### Executive Summary

No thesis match: MRS_20 3.0% below STRENGTH zone (4.0-10.0%); PEG 1.93 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($338.51)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Snap-On (NYSE:SNA) CFO Sells $2,387,563.80 in Stock**
- Source: MarketBeat | 20251213T004034 | Somewhat-Bearish | Relevance: 100%
- Snap-On CFO Aldo John Pagliari sold 6,779 shares of company stock for $2,387,563.80, reducing his stake by 5.71%. The company recently increased its quarterly dividend to $2.44 and reported quarterly earnings that exceeded analyst expectations. Snap-On maintains a "Moderate Buy" consensus rating with an average analyst price target of $365.00.

**2. Sei Investments Co. Increases Stake in Snap-On Incorporated $SNA**
- Source: MarketBeat | 20251212T110132 | Somewhat-Bullish | Relevance: 100%
- Sei Investments Co. has increased its stake in Snap-On Incorporated (NYSE:SNA) by 3.4% during the second quarter, now holding 373,356 shares worth approximately $116 million. This comes as other institutional investors have also adjusted their positions in the company. Snap-On recently reported strong earnings, beating analyst estimates, and increased its quarterly dividend.

**3. Axa S.A. Purchases 58,343 Shares of Snap-On Incorporated $SNA**
- Source: MarketBeat | 20251211T083918 | Somewhat-Bullish | Relevance: 100%
- Axa S.A. has significantly increased its stake in Snap-On Incorporated, purchasing an additional 58,343 shares and increasing its holdings by 310.5%. This brings Axa S.A.'s total ownership to 77,132 shares, valued at $24,002,000. Other institutional investors have also adjusted their positions in Snap-On, while several company insiders have recently sold shares.

**4. Is Stanley Black & Decker Stock Underperforming the Nasdaq?**
- Source: inkl | 20251215T120848 | Neutral | Relevance: 73%
- Stanley Black & Decker (SWK) stock has underperformed the Nasdaq Composite over the past three months and the last year, despite a 12.3% gain over six months. The company's weak performance is attributed to declining sales volumes, though its Q3 adjusted EPS exceeded Wall Street expectations. Analysts have a "Moderate Buy" rating for SWK, with a potential upside of 7.5% from current levels.

**5. Is CapsoVision Showing How Far A Single Capsule Can Take A Med-Tech Company?**
- Source: RTTNews | 20251211T090957 | Somewhat-Bullish | Relevance: 64%
- CapsoVision Inc. (CV) has garnered significant attention following a sharp rise in trading activity and share price, closing up 32.73% and continuing to climb in after-hours trading. The company, which specializes in endoscopic video imaging devices for GI visualization, is expanding its commercial footprint with products like CapsoCam Plus and advancing new clinical programs such as a Breakthrough Device Designation application for pancreatic cancer detection. CapsoVision's strong financial performance, strategic partnerships, and technological advancements position it as a company to watch in the medical technology sector.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.01M) |
| Sells | 7 ($2.10M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (-0.0%)
- Blackrock Inc.: 7.8% (-0.8%)
- State Street Corpora: 4.3% (+1.6%)
- Charles Schwab Inves: 3.8% (+0.7%)
- First Trust Advisors: 3.7% (+1.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +2.2% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.93 elevated, pricing in significant growth expectations. Forward P/E 17.1x stretched relative to 7% growth. Quality metrics strong (margin 20%). Balance sheet: strong liquidity (4.4x), low leverage (D/E 0.43). Insider selling cluster ($2.1M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.3B |
| Beta | 0.78 |
| 52W Range | $289.81 - $365.78 |
| Short Interest | 5.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.93 |
| Forward P/E | 17.1 |
| Current P/E | 18.2 |
| YoY Growth | 6.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 0.8% to 3.0% (+2.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.0pp (needs >4.0% for momentum thesis). MRS_5 at 2.1% confirms short-term momentum alignment. AM_20 at 3.4% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.31), confirming momentum. Elevated volume (1.3x 20MA), institutional activity likely. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.99% (CS: 61) | Neutral |
| RSI_14 | 62.9 | Neutral |
| MACD Histogram | 1.31 | Bullish |
| vs SMA20 | 1.032x | Above |
| vs SMA50 | 1.032x | Above |
| vs SMA200 | 1.068x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $350.83
- **Stop Loss:** $338.51 (3.5% risk)
- **Target:** $363.15 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 97
- **Position Value:** $34,030.51
- **Portfolio %:** 34.03%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-05 (Est: $4.92)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.64 | $5.02 | +8.1% |
| 2025Q2 | $4.63 | $4.72 | +2.0% |
| 2025Q1 | $4.82 | $4.51 | -6.4% |
| 2024Q4 | $4.79 | $4.82 | +0.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*